[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Insulin Delivery Devices Market (By Device Type: insulin pumps, insulin syringes, insulin pens and insulin jet injectors; By Geography: North America, Europe, Asia-Pacific and RoW) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024

September 2017 | 115 pages | ID: I4DCD348444EN
Variant Market Research

US$ 3,195.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Insulin Delivery Devices Market is estimated to reach $22.8 billion by 2024; growing at a CAGR of 8.9% from 2016 to 2024. Insulin is generally produced in pancreas, and play an important role in regulating blood glucose level and metabolism. People with type 1 and type 2 diabetes have to take insulin shots owing to their inability to respond to insulin or lack of insulin production. This will aid to prevent the body in processing glucose, avoid complexity associated to hyperglycemia and prevent other long-term complications. Synthetic insulins are most generally prescribed insulin for medication and are commonly injected through syringe, insulin pumps, injection pen, and others. Devices used for delivering insulin varies among end-users depending upon their ability to operate, insurance coverage, insulin regimen, and others.

The growth of the global insulin delivery market can be attributed to increasing geriatric and obese population, technological advancements, supporting government policies, rising awareness among end-users, and development of human insulin devices. Additionally, untapped market and increasing research & development activities could provide future scope in the coming years. Though, high price of these devices and risk of misusage of drug delivery devices may limit the growth of the market.

The global insulin delivery devices market is segmented into device type and geography. Device type is categorized into insulin syringes, insulin pumps, insulin pumps, and insulin jet injectors. By geography, the market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The U.S., Canada, and Mexico are covered under North America wherein Europe covers UK, Germany, France, Italy, Spain, and others. Asia-Pacific covers China, Japan, India, and others. RoW covers South America, Middle East, and Africa.

The key players operating in the market include Medtronic plc, Novo Nordisk A/S, Tandem Diabetes Care, Inc., Eli Lilly and Company, Ypsomed Holding AG, F. Hoffmann-La Roche, Ltd., Becton, Dickinson and Company, Animas Corporation, B. Braun Melsungen AG, and Insulet Corporation, among others.

THE KEY TAKEAWAYS FROM THE REPORT
  • The report will provide a detailed analysis of Global Insulin Delivery Devices Market with respect to major segments such as device type and geography
  • The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
  • Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
  • An exhaustive regional analysis of Global Insulin Delivery Devices Market from 2015 to 2024 has been included in the report
  • Profile of the key players in the Global Insulin Delivery Devices will be provided, which include key financials, product & services, new developments and business strategies
SCOPE OF THE GLOBAL INSULIN DELIVERY DEVICES MARKET

Device Type Segments
  • Insulin Syringes
  • Insulin Pumps
  • Insulin Pumps
  • Insulin Jet Injectors
Geography Segments
  • North America
    • U.S.
    • Canada
        • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Other
  • Asia-Pacific
    • China
    • Japan
    • India
    • Others
  • RoW
    • South America
    • Middle East
    • Africa
CHAPTER 1 PREFIX

1.1 Market Scope
1.2 Report Description
1.3 Research Methodology
  1.3.1 Primary Research
  1.3.2 Secondary Research
  1.3.3 In-house Data Modeling

CHAPTER 2 EXECUTIVE SUMMARY


CHAPTER 3 MARKET OUTLINE

3.1 Market Inclination, Trend, Outlook and Viewpoint
3.2 Market Share Analysis: Company’s Competitive Scenario
3.3 Market Dynamics
  3.3.1 Drivers
    3.3.1.1 Impact Analysis
  3.3.2 Restraints
    3.4.2.1 Impact Analysis
  3.3.3 Opportunities

CHAPTER 4 INSULIN DELIVERY DEVICES MARKET BY DEVICE TYPE: MARKET SIZE AND FORECAST, 2015 – 2024

4.1 Overview
4.2 Insulin Pumps
  4.2.1 Current Trend and Analysis
  4.2.2 Market Size and Forecast
4.3 Insulin Syringes
  4.3.1 Current Trend and Analysis
  4.3.2 Market Size and Forecast
4.4 Insulin Pens
  4.4.1 Current Trend and Analysis
  4.4.2 Market Size and Forecast
4.5 Insulin Jet Injectors
  4.5.1 Current Trend and Analysis
  4.5.2 Market Size and Forecast

CHAPTER 5 INSULIN DELIVERY DEVICES MARKET BY GEOGRAPHY: MARKET SIZE AND FORECAST, 2015 – 2024

5.1 Overview
5.2 North America
  5.2.1 Current Trend and Analysis
  5.2.2 Market Size and Forecast
  5.2.3 US
    5.2.3.1 Market Size and Forecast
  5.2.4 Canada
    5.2.4.1 Market Size and Forecast
  5.2.5 Mexico
    5.2.5.1 Market Size and Forecast
5.3 Europe
  5.3.1 Current Trend and Analysis
  5.3.2 Market Size and Forecast
  5.3.3 Germany
    5.3.3.1 Market Size and Forecast
  5.3.4 France
    5.3.4.1 Market Size and Forecast
  5.3.5 United Kingdom
    5.3.5.1 Market Size and Forecast
  5.3.6 Italy
    5.3.6.1 Market Size and Forecast
  5.3.7 Spain
    5.3.7.1 Market Size and Forecast
  5.3.8 Others
    5.3.8.1 Market Size and Forecast
5.4 Asia-Pacific
  5.4.1 Current Trend and Analysis
  5.4.2 Market Size and Forecast
  5.4.3 China
    5.4.3.1 Market Size and Forecast
  5.4.4 India
    5.4.4.1 Market Size and Forecast
  5.4.5 Japan
    5.4.5.1 Market Size and Forecast
  5.4.6 Others
    5.4.6.1 Market Size and Forecast
5.5 RoW
  5.5.1 Current Trend and Analysis
  5.5.2 Market Size and Forecast
  5.5.3 Middle East
    5.5.3.1 Market Size and Forecast
  5.5.4 South America
    5.5.4.1 Market Size and Forecast
  5.5.5 Africa
    5.5.5.1 Market Size and Forecast

CHAPTER 6 COMPANY PROFILES

6.1 Medtronic plc
6.2 Eli Lilly and Company
6.3 Becton, Dickinson and Company
6.4 Tandem Diabetes Care, Inc.
6.5 Ypsomed Holding AG
6.6 F. Hoffmann-La Roche, Ltd.
6.7 Animas Corporation
6.8 Novo Nordisk A/S
6.9 B. Braun Melsungen AG
6.10 Insulet Corporation


More Publications